<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>World Pharma Today</title>
	<atom:link href="https://www.worldpharmatoday.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Wed, 01 Jul 2026 06:02:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>World Pharma Today</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Shilpa Biologicals Launches Integrated ADC Production Site in India</title>
		<link>https://www.worldpharmatoday.com/press-releases/shilpa-biologicals-launches-integrated-adc-production-site-in-india/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 01 Jul 2026 06:02:32 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/shilpa-biologicals-launches-integrated-adc-production-site-in-india/</guid>

					<description><![CDATA[<p>Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd, has officially commissioned an advanced integrated Antibody–Drug Conjugate (ADC) GMP manufacturing site in Dharwad. Announced on 25 June 2026, the facility was specifically engineered to satisfy the rigorous global regulatory standards of the US FDA, EMA, and other prominent health authorities. This ADC manufacturing facility is [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/shilpa-biologicals-launches-integrated-adc-production-site-in-india/">Shilpa Biologicals Launches Integrated ADC Production Site in India</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing</title>
		<link>https://www.worldpharmatoday.com/press-releases/cphi-milan-2026-unveils-dedicated-innovation-hubs-for-pharma-manufacturing/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 01 Jul 2026 05:42:24 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cphi-milan-2026-unveils-dedicated-innovation-hubs-for-pharma-manufacturing/</guid>

					<description><![CDATA[<p>CPHI Milan 2026, recognized as a premier global gathering for the pharmaceutical industry, has announced the introduction of four new specialist zones for pharma at its upcoming event. Scheduled for October 6-8, 2026, at the Fiera Milan exhibition centre in Rho, Italy, these specialized areas will focus on AI &#38; Tech, Cold Chain &#38; Logistics, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/cphi-milan-2026-unveils-dedicated-innovation-hubs-for-pharma-manufacturing/">CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Eschbach Unveils a New Era of Intelligent Operations</title>
		<link>https://www.worldpharmatoday.com/videos/eschbach-unveils-a-new-era-of-intelligent-operations/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 30 Jun 2026 09:13:12 +0000</pubDate>
				<category><![CDATA[Videos]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/eschbach-unveils-a-new-era-of-intelligent-operations/</guid>

					<description><![CDATA[<p>In this exclusive interview with World Pharma Today, industry experts discuss the evolving role of digital transformation in pharmaceutical manufacturing and how intelligent operations platforms are helping organizations navigate an increasingly complex operating environment. Featuring insights from SEQONIS by eschbach, the conversation explores how modern pharmaceutical companies are moving beyond traditional operational systems to embrace [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/videos/eschbach-unveils-a-new-era-of-intelligent-operations/">Eschbach Unveils a New Era of Intelligent Operations</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>In Vivo CAR-T Engineering Sets a New Oncology Standard</title>
		<link>https://www.worldpharmatoday.com/drug-research/in-vivo-car-t-engineering-sets-a-new-oncology-standard/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:52:49 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/in-vivo-car-t-engineering-sets-a-new-oncology-standard/</guid>

					<description><![CDATA[<p>The emergence of chimeric antigen receptor T cell therapy has been one of the most significant breakthroughs in the history of hematology oncology. By re engineering a patient’s own immune cells to recognize and attack cancer, researchers have achieved unprecedented remission rates in patients with advanced leukemias and lymphomas. However, the current generation of CAR-T [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/in-vivo-car-t-engineering-sets-a-new-oncology-standard/">In Vivo CAR-T Engineering Sets a New Oncology Standard</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Radioligand Therapy Advances in Precision Oncology</title>
		<link>https://www.worldpharmatoday.com/drug-research/radioligand-therapy-advances-in-precision-oncology/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:52:33 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/radioligand-therapy-advances-in-precision-oncology/</guid>

					<description><![CDATA[<p>The oncology sector is witnessing a fundamental change in the way systemic radiation is delivered to patients. Historically, radiotherapy was administered from an external source, which, while effective at killing tumor cells, often caused significant damage to the surrounding healthy tissue. This limitation necessitated a move toward more targeted approaches that could deliver therapeutic radiation [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/radioligand-therapy-advances-in-precision-oncology/">Radioligand Therapy Advances in Precision Oncology</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Proximity Therapeutics Unlock New Druggable Frontiers</title>
		<link>https://www.worldpharmatoday.com/drug-research/proximity-therapeutics-unlock-new-druggable-frontiers/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:52:09 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/proximity-therapeutics-unlock-new-druggable-frontiers/</guid>

					<description><![CDATA[<p>The pharmaceutical industry has historically focused on a narrow subset of the human proteome. For decades, the majority of small molecule drugs were designed to bind to the active sites of enzymes or receptors, effectively inhibiting their function. While this approach has been successful for many conditions, it is estimated that nearly eighty percent of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/proximity-therapeutics-unlock-new-druggable-frontiers/">Proximity Therapeutics Unlock New Druggable Frontiers</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CDMO Strategies Powering the Next-Gen Biopharma Surge</title>
		<link>https://www.worldpharmatoday.com/biopharma/cdmo-strategies-powering-the-next-gen-biopharma-surge/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:51:15 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cdmo-strategies-powering-the-next-gen-biopharma-surge/</guid>

					<description><![CDATA[<p>The biopharmaceutical sector is currently navigating an era of unprecedented growth and technological complexity. As the global drug pipeline shifts toward advanced modalities such as cell and gene therapies, bispecific antibodies, and complex mRNA formulations, the demands placed on manufacturing infrastructure have reached a critical point. Many emerging biotech firms and even established pharmaceutical giants [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/cdmo-strategies-powering-the-next-gen-biopharma-surge/">CDMO Strategies Powering the Next-Gen Biopharma Surge</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Why Pharma Supply Chain Resilience Demands Immediate Action</title>
		<link>https://www.worldpharmatoday.com/business-industry/why-pharma-supply-chain-resilience-demands-immediate-action/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:50:42 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/why-pharma-supply-chain-resilience-demands-immediate-action/</guid>

					<description><![CDATA[<p>The global pharmaceutical industry is currently facing a critical period of self reflection regarding the stability and reliability of its logistics networks. For years, the sector prioritized cost optimization and just in time manufacturing, leading to a highly centralized and lean distribution model. While this approach was efficient under stable conditions, the recent wave of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/business-industry/why-pharma-supply-chain-resilience-demands-immediate-action/">Why Pharma Supply Chain Resilience Demands Immediate Action</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>AI Automation Is Accelerating Drug Discovery at Scale</title>
		<link>https://www.worldpharmatoday.com/drug-research/ai-automation-is-accelerating-drug-discovery-at-scale/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:50:18 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/ai-automation-is-accelerating-drug-discovery-at-scale/</guid>

					<description><![CDATA[<p>The traditional pharmaceutical research and development model has long been characterized by high costs, long timelines, and a high rate of failure. For every drug that successfully reaches the market, thousands of candidates fall by the wayside during the discovery and preclinical phases. This inefficiency is a significant burden on the industry, limiting the number [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/ai-automation-is-accelerating-drug-discovery-at-scale/">AI Automation Is Accelerating Drug Discovery at Scale</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Extracellular Vesicles and the Future of Cell-Free Therapy</title>
		<link>https://www.worldpharmatoday.com/biopharma/extracellular-vesicles-and-the-future-of-cell-free-therapy/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:49:49 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/extracellular-vesicles-and-the-future-of-cell-free-therapy/</guid>

					<description><![CDATA[<p>The transition from living cell therapies to cell free alternatives represents one of the most significant shifts in modern biotechnology. For years, the regenerative medicine sector has relied on the transplantation of whole cells to repair tissues and modulate the immune system. While these approaches have shown clinical efficacy, they are often hindered by complex [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/extracellular-vesicles-and-the-future-of-cell-free-therapy/">Extracellular Vesicles and the Future of Cell-Free Therapy</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
